NCT05918042Completed
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation
Multicentre, Non-interventional, Observational, Prospective Study to Evaluate 1-st Line Treatment Approaches in HRD+ Ovarian Cancer Patients in Russian Federation
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history. It is estimated that approximately 400 patients will be enrolled in approximately 25 sites. Demographic and clinical characteristics, treatment approaches and outcomes in HRD+ patients with high-grade epithelial ovarian, primary peritoneal, and/or fallopian tube cancer will be collected at baseline and on prospective visits.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 414 (actual)
- First submitted
- 15 Jun 2023
- Start date
- 21 Jun 2023
- Primary completion date
- 29 May 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Ovarian cancer
- NCT number
- NCT05918042
What you commit to
- Study type: Observational
- Participants enrolled: 414
- From 21 Jun 2023 to the primary completion date, 29 May 2025
- 24 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients participating in other clinical studies
Who the study is looking for
- Patients ≥18 years of age;
- Willing and ability to provide written informed consent for participation in the study;
- Known status HRD+ (positive BRCAm test and/or positive Genomic Instability test);
- Patients with histologically confirmed diagnosis of high-grade IC-IV FIGO stages epithelial ovarian, primary peritoneal, and/or fallopian tube cancer;
- Completed primary treatment (surgery and/or 1st line CT +/- bevacizumab) no more than 3 months after completion of primary treatment.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (24)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.